Loading organizations...
BioTelemetry, Inc. develops mobile and wireless medical technology for monitoring health information. The company manufactures medical equipment, providing centralized medical imaging, cardiac, and mobile blood-glucose monitoring services. Its technology delivers crucial health data, enabling continuous oversight of patient conditions for better health outcomes.
Founded approximately a quarter-century ago, BioTelemetry emerged with a steadfast commitment to advancing the mobile and wireless medical technology industry. The company has consistently focused on innovating solutions within the digital health sector, establishing itself as a key player in remote patient monitoring.
BioTelemetry serves both the broader healthcare and specialized clinical research sectors, primarily within the United States. The company's vision centers on the delivery of health information to improve lives and reduce care costs through its wireless medical technology. It aims to remain a leader in mobile health information, continually expanding its impact on patient care.
Biotel has 1 tracked investment across 1 company. The latest tracked deal is $27.0M Series C Extension in BioSight in December 2020.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Dec 2, 2020 | BioSight | $27.0M Series C Extension | David Sidransky | Arkin BIO Ventures, Migdal Insurance, Primera Capital, The Phoenix Insurance Company |